Evaluating Circulating DNA to Detect Residual Disease After Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Led by Centre Jean Perrin · Updated on 2026-09-11
59
Participants Needed
4
Research Sites
117 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying circulating DNA cDNA as a potential biomarker to detect residual disease following chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma. This ancillary clinical trial focuses on whether cDNA can identify residual disease three months after treatment by comparing cDNA detection results with clinical and radiological assessments.
Participants will undergo blood sampling, where 18 mL of blood is collected at one and three months after completing chemoradiotherapy. These blood samples are used to assess the presence and kinetics of circulating DNA, and researchers will also study mutational profiles and HPV genotypes in relation to the tumor and ctDNA at diagnosis.
During the trial, participants provide blood samples at specified times and are monitored for objective response to treatment and survival outcomes. Researchers measure cDNA detection and compare it with clinical responses at one and three months post-treatment. The study is conducted alongside the main Neck-TAR study, and participation involves blood draws and follow-up evaluations up to 27 months after treatment to assess progression-free and overall survival.
CONDITIONS
Brief Title
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Research Team
A
Angeline GINZAC COUVÉ Project manager, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Written informed consent signed for NeckTAR-IN study
Affiliation to the French social security system
You will not qualify if you...
None explicitly stated in the eligibility criteria
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Sample Collection and Monitoring
Duration - 3 months
Participants provide blood samples at one and three months after completing chemoradiotherapy to assess circulating DNA and monitor residual disease.
2 visits for blood sampling
Follow-up
Duration - Up to 27 months after treatment
Participants are monitored for progression-free and overall survival outcomes as part of the main Neck-TAR study, with ongoing evaluations up to 27 months after treatment.
Periodic follow-up visits per main study schedule
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
Evaluating Circulating DNA to Detect Residual Disease After Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 12 Study of Gabapentin and Intranasal Ketamine for Preventing and Treating Pain in Adults with Locally Advanced Head and Neck Cancer Undergoing Chemoradiation
Comparing Neoadjuvant Immunochemotherapy Plus Surgery Versus Standard Surgery and Adjuvant Therapy
for Locally Advanced Oral Squamous Cell Carcinoma
A Multicenter Randomized Phase 3 Trial
Evaluating Circulating DNA to Predict Residual Disease After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer
Phase I Study of Thermotherapy Added to Standard Chemoradiotherapy or Radiotherapy for Locally Advanced Head and Neck Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Prospective multicentre study evaluating ctDNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: NeckTAR-IN protocol.